More recently, these inhibitors have demonstrated promising potential in non-cancer indications, owing to their multi-kinase activity and off-target inhibition of kinases such as PDGFR, c-KIT, FLT3, and native ABL1 [2]. Here, ABL1 is linked to cancer.